[ad_1]
Abu Dhabi, United Arab Emirates: Speed, consistency, and cost are the words most commonly used to describe the inherent benefits of AI applied to healthcare. Nonetheless, there is another key descriptor that is almost always overlooked in discussions – personalization.
When experts try to explain the impact of AI on the world’s seemingly unmanageable healthcare systems, they often turn to statistics to put the magnitude of the disease burden in a given population into context. AI appears designed to address these numerous, diverse, and complex healthcare challenges through a range of disruptive technologies that are thought to solve problems quickly and consistently, making it an important topic for those in the industry, from drug developers to nursing practitioners. ,low cost.
To be sure, artificial intelligence will not provide the proverbial “panacea” to cure human pain and suffering in the world overnight, but it will help us understand extremely complex life science problems that previously may have cost us It takes months, years and, in some cases, decades to better understand.
Now, thanks to a series of recent healthcare industry partnerships and collaborations, the UAE’s Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) – as the world’s first graduate research university dedicated to artificial intelligence – It is presenting in a very public way its unique mission to conduct major research for individualized solutions aimed at the advancement of society.
In March, MBZUAI and network test The two parties signed a five-year research and development agreement to form a joint research laboratory to develop personalized digital therapeutics for human brain health by optimizing the power of artificial intelligence technology.
The collaboration aims to leverage IBT’s capabilities in developing and commercializing digital therapeutics and MBZUAI’s expertise in artificial intelligence, with the ultimate goal of enabling powerful, personalized treatments for brain and mental disorders. Considering that the World Health Organization (WHO) estimates that more than one in eight people in the world (approximately 1 billion people) suffer from some type of mental illness, depression, this personalized approach to mental health treatment is an ambitious one. The goal is according to WHO’s World Mental Health Report: Transforming mental health for all.
In early March, MBZUAI announced a historic Memorandum of Understanding (MoU) biological mapa disruptive ultra-large-scale artificial intelligence model-driven life science platform, to establish a biocomputing innovation research laboratory, which will be the first of its kind in the Middle East.
Under the terms of the MOU, the parties have agreed to focus on breakthroughs in artificial intelligence-generated proteins (AIGP) based on the Middle East’s most pressing needs in healthcare, drug design and other critical areas. MBZUAI and BioMap aim to leverage joint capabilities to explore new technologies to advance protein generation, protein structure prediction, cell function prediction, and other fundamental life science challenges.
One such challenge is age-related diseases, with the World Health Organization estimating that the global population aged 60 and over will double to 2.1 billion by 2050. MBZUAI and BioMap have agreed to collaborate on the use of large-scale AI models for multi-omics predictions – training to accelerate the discovery of drug targets for aging-related diseases, thereby facilitating the development of personalized treatments.
In January 2023, MBZUAI and Kuris artificial intelligence Develop a world-class Bio-AI Center in Abu Dhabi, a state-of-the-art facility to support faster development of safer, more highly personalized medicines, tailored specifically for diverse populations in the MENA region .
Quris-AI is the world’s first bio-AI clinical prediction platform, which ensures the safety of new drugs by innovating the drug development process and groundbreaking clinical trials on a chip-testing thousands of new drug candidates on hundreds of miniaturized “patients” and effectiveness. chip”.
Currently, about 90 percent of clinical trials for new drugs fail, but their proprietary “patient-on-a-chip” technology promises to reduce losses by predicting which drugs are most likely to work in humans, Quris-AI executives said. The Quris-AI system rapidly performs test interactions using predictive AI technology that mimics genetically diverse patients, eliminating the need for animal testing and avoiding the risks and costs associated with clinical trial failure.
The personalized global healthcare solutions of tomorrow are becoming possible through cutting-edge artificial intelligence research projects being launched in Abu Dhabi today, but through collaboration and collaboration with some of the world’s most innovative companies and the people they make up Completed. Now, this is the education of all future leaders in AI research and innovation.
-over-
About Mohamed bin Zayed University of Artificial Intelligence (MBZUAI)
MBZUAI is a research university focusing on artificial intelligence, computer science and digital technologies across industries. The University aims to empower students, businesses and governments to advance artificial intelligence as a global force for positive progress. MBZUAI offers a variety of graduate programs designed to pursue advanced expertise and skills in artificial intelligence, including computer vision, machine learning and natural language processing. For more information, please visit www.mbzuai.ac.ae
To apply for admission, visit mbzuai.ac.ae or contact admissions@mbzuai.ac.ae
For press inquiries, please contact:
Zokuri Aya
Director of Communications
media@mbzuai.ac.ae
Roger Field/Aya Abunawa
Wallis PR
mbzuai@wallispr.com
[ad_2]
Source link